Evaluation of Brain Targeting and Antipsychotic Activity of Nasally Administrated Ziprasidone Lipid-Polymer Hybrid Nanocarriers

• Published in: Pharmaceuticals (Basel, Switzerland) Vol. 16; no. 6; p. 886
• Main Authors: Abo El-Enin, Hadel A, Tulbah, Alaa S, Darwish, Hany W, Salama, Rania, Naguib, Ibrahim A, Yassin, Heba A, Abdel-Bar, Hend Mohamed
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.06.2023; MDPI
• Subjects: Antipsychotics; brain targeting; Cholesterol; Cytotoxicity; Dosage and administration; Drug delivery systems; Drug targeting; Drugs; Evaluation; intranasal; Lipids; lipid–polymer hybrid; Materials; nanocarriers; Nanomedicine; Nose; Particle size; Pharmacokinetics; Polymers; Psychotropic drugs; Testing; Vehicles; Ziprasidone; Egypt; intranasal; ziprasidone; lipid–polymer hybrid; brain targeting; nanocarriers
• ISSN: 1424-8247; 1424-8247
• DOI: 10.3390/ph16060886

The feasibility of using lipid-polymer hybrid (LPH) nanocarriers as a potential platform for the intranasal delivery of ziprasidone (ZP), a second-generation antipsychotic, was explored. Different ZP-loaded LPH composed of a PLGA core and cholesterol-lecithin lipid coat were prepared using a single step nano-precipitation self-assembly technique. Modulation of polymer, lipid and drug amounts, as well as stirring-speed-optimized LPH with a particle size of 97.56 ± 4.55 nm and a ZP entrapment efficiency (EE%) of 97.98 ± 1.22%. The brain deposition and pharmacokinetics studies proved the efficiency of LPH to traverse the blood-brain barrier (BBB) following intranasal delivery with a 3.9-fold increase in targeting efficiency compared to the intravenous (IV) ZP solution with a direct nose-to-brain transport percentage (DTP) of 74.68%. The ZP-LPH showed enhanced antipsychotic activity in terms of animals' hypermobility over an IV drug solution in schizophrenic rats. The obtained results showed that the fabricated LPH was able to improve ZP brain uptake and proved its antipsychotic efficiency.